Browse LBP

Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Cytoplasmic granule membrane Note=Membrane-associated in polymorphonuclear Leukocytes (PMN) granules.
Domain PF01273 LBP / BPI / CETP family
PF02886 LBP / BPI / CETP family
Function

Plays a role in the innate immune response. Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria (PubMed:7517398, PubMed:24120359). Acts as an affinity enhancer for CD14, facilitating its association with LPS. Promotes the release of cytokines in response to bacterial lipopolysaccharide (PubMed:7517398, PubMed:24120359).

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002232 leukocyte chemotaxis involved in inflammatory response
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002281 macrophage activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002523 leukocyte migration involved in inflammatory response
GO:0002526 acute inflammatory response
GO:0002532 production of molecular mediator involved in inflammatory response
GO:0002536 respiratory burst involved in inflammatory response
GO:0002679 respiratory burst involved in defense response
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006869 lipid transport
GO:0006909 phagocytosis
GO:0006953 acute-phase response
GO:0006968 cellular defense response
GO:0008228 opsonization
GO:0009595 detection of biotic stimulus
GO:0010876 lipid localization
GO:0015920 lipopolysaccharide transport
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031349 positive regulation of defense response
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032490 detection of molecule of bacterial origin
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0032640 tumor necrosis factor production
GO:0032642 regulation of chemokine production
GO:0032675 regulation of interleukin-6 production
GO:0032677 regulation of interleukin-8 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032722 positive regulation of chemokine production
GO:0032755 positive regulation of interleukin-6 production
GO:0032757 positive regulation of interleukin-8 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034123 positive regulation of toll-like receptor signaling pathway
GO:0034142 toll-like receptor 4 signaling pathway
GO:0034143 regulation of toll-like receptor 4 signaling pathway
GO:0034145 positive regulation of toll-like receptor 4 signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042116 macrophage activation
GO:0042533 tumor necrosis factor biosynthetic process
GO:0042534 regulation of tumor necrosis factor biosynthetic process
GO:0042535 positive regulation of tumor necrosis factor biosynthetic process
GO:0042742 defense response to bacterium
GO:0043030 regulation of macrophage activation
GO:0043032 positive regulation of macrophage activation
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044110 growth involved in symbiotic interaction
GO:0044116 growth of symbiont involved in interaction with host
GO:0044117 growth of symbiont in host
GO:0044126 regulation of growth of symbiont in host
GO:0044130 negative regulation of growth of symbiont in host
GO:0044144 modulation of growth of symbiont involved in interaction with host
GO:0044146 negative regulation of growth of symbiont involved in interaction with host
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045730 respiratory burst
GO:0045926 negative regulation of growth
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050829 defense response to Gram-negative bacterium
GO:0050830 defense response to Gram-positive bacterium
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0060263 regulation of respiratory burst
GO:0060264 regulation of respiratory burst involved in inflammatory response
GO:0060265 positive regulation of respiratory burst involved in inflammatory response
GO:0060267 positive regulation of respiratory burst
GO:0060326 cell chemotaxis
GO:0070391 response to lipoteichoic acid
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071223 cellular response to lipoteichoic acid
GO:0071396 cellular response to lipid
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071624 positive regulation of granulocyte chemotaxis
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0090022 regulation of neutrophil chemotaxis
GO:0090023 positive regulation of neutrophil chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0098542 defense response to other organism
GO:0098581 detection of external biotic stimulus
GO:1901264 carbohydrate derivative transport
GO:1902622 regulation of neutrophil migration
GO:1902624 positive regulation of neutrophil migration
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001530 lipopolysaccharide binding
GO:0070891 lipoteichoic acid binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-449147: Signaling by Interleukins
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-166020: Transfer of LPS from LBP carrier to CD14
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LBP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LBP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LBP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9070.265
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2480.852
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.4070.192
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.1340.0141
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-3.4210.00983
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5170.736
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5350.615
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6480.674
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3840.813
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3470.439
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3320.573
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5960.16
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LBP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LBP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LBP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LBP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LBP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LBP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LBP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLBP
Namelipopolysaccharide binding protein
Aliases BPIFD2; BPI fold containing family D, member 2; lipopolysaccharide-binding protein; LPS-binding protein
Chromosomal Location20q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LBP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.